{"id":"W4405287327","doi":"10.1016/j.annonc.2024.12.003","title":"Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma","year":2024,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; EMD Serono; Genentech; Institut Servier; Ipsen; Eisai; Incyte; Deciphera Pharmaceuticals; Harvard Medical School; Gilead Sciences; Exelixis; Servier; Memorial Sloan-Kettering Cancer Center; Dana-Farber/Harvard Cancer Center; GlaxoSmithKline; Dana-Farber Cancer Institute; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Biomarker; Oncology; Internal medicine; Kidney cancer; Cancer; Immunotherapy; Sorafenib; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004144285,0.00139805,0.003292976,0.0004662077,0.0004467074,0.001561808,0.000758374,0.001116506,0.003707401],"category_scores_gemma":[0.004194929,0.0005546736,0.003833102,0.0005681268,0.0007540873,0.001563449,0.0005354679,0.003049193,0.000560121],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001355471,"about_ca_system_score_gemma":0.001739691,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001152595,"about_ca_topic_score_gemma":0.003330704,"domain_scores_codex":[0.998363,0.001009285,0.00009592978,0.0002434796,0.000150098,0.0001382579],"domain_scores_gemma":[0.9980196,0.0006954105,0.0005602051,0.0001864681,0.0001799842,0.0003582691],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9363164,0.002503227,0.006018147,0.00106681,0.009317715,0.00004880874,0.00005828719,0.002098235,0.004411204,0.0002475939,0.003376422,0.03453708],"study_design_scores_gemma":[0.8489678,0.08938553,0.03631146,0.0001612705,0.01439641,0.000211312,0.0001118909,0.002332045,0.002056194,0.001103017,0.004892768,0.00007038619],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772694,0.01370354,0.0007637064,0.001886483,0.0004225688,0.001166563,0.002839308,0.00009849378,0.001850044],"genre_scores_gemma":[0.9875699,0.002887964,0.001648493,0.001158181,0.0002721566,0.001048333,0.004002662,0.00003711922,0.001375152],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004144285,"threshold_uncertainty_score":0.02191734,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2315162053387895,"score_gpt":0.4599142363737644,"score_spread":0.228398031034975,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}